Fennec Pharmaceuticals Inc. Share Price Nasdaq
Equities
CA31447P1009
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.255 USD | 0.00% | 0.00% | 0.00% |
Sales 2024 * | 50.21M 4.02B | Sales 2025 * | 71.15M 5.69B | Capitalization | 255M 20.44B |
---|---|---|---|---|---|
Net income 2024 * | 7M 560M | Net income 2025 * | 26M 2.08B | EV / Sales 2024 * | 5.09 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.59 x |
P/E ratio 2024 * |
36
x | P/E ratio 2025 * |
10
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.7% |
Latest transcript on Fennec Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 06/07/09 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 06/07/09 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 24/04/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 24/08/11 |
Khalid Islam
CHM | Chairman | 67 | 24/04/14 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 06/07/09 |
1st Jan change | Capi. | |
---|---|---|
+4.23% | 106B | |
+7.02% | 23.47B | |
-14.44% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.20% | 16.78B | |
+6.94% | 14.41B | |
+35.80% | 12.86B | |
+317.76% | 8.78B |